These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 30706425)

  • 1. L-Ornithine L-Aspartate (LOLA) for Hepatic Encephalopathy in Cirrhosis: Results of Randomized Controlled Trials and Meta-Analyses.
    Butterworth RF; McPhail MJW
    Drugs; 2019 Feb; 79(Suppl 1):31-37. PubMed ID: 30706425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of L-ornithine L-aspartate for minimal hepatic encephalopathy in patients with cirrhosis: A meta-analysis of randomized controlled trials.
    He Q; Mao C; Chen Z; Zeng Y; Deng Y; Hu R
    Arab J Gastroenterol; 2024 May; 25(2):84-92. PubMed ID: 38403493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beneficial effects of L-ornithine L-aspartate for prevention of overt hepatic encephalopathy in patients with cirrhosis: a systematic review with meta-analysis.
    Butterworth RF
    Metab Brain Dis; 2020 Jan; 35(1):75-81. PubMed ID: 31338724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. l-ornithine-l-aspartate for hepatic encephalopathy in patients with cirrhosis: a meta-analysis of randomized controlled trials.
    Bai M; Yang Z; Qi X; Fan D; Han G
    J Gastroenterol Hepatol; 2013 May; 28(5):783-92. PubMed ID: 23425108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis.
    Goh ET; Stokes CS; Sidhu SS; Vilstrup H; Gluud LL; Morgan MY
    Cochrane Database Syst Rev; 2018 May; 5(5):CD012410. PubMed ID: 29762873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of l-Ornithine l-Aspartate for the Treatment of Hepatic Encephalopathy and Hyperammonemia in Cirrhosis: Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Butterworth RF; Kircheis G; Hilger N; McPhail MJW
    J Clin Exp Hepatol; 2018 Sep; 8(3):301-313. PubMed ID: 30302048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary prophylaxis of hepatic encephalopathy in cirrhosis of liver: a double-blind randomized controlled trial of L-ornithine L-aspartate versus placebo.
    Varakanahalli S; Sharma BC; Srivastava S; Sachdeva S; Dahale AS
    Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):951-958. PubMed ID: 29727385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous versus oral 'L-ornithine-L-aspartate' in overt hepatic encephalopathy: a randomized comparative study.
    Jhajharia A; Singh S; Jana S; Ashdhir P; Nijhawan S
    Sci Rep; 2024 May; 14(1):11862. PubMed ID: 38789596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomised clinical trial: L-ornithine-L-aspartate reduces significantly the increase of venous ammonia concentration after TIPSS.
    Bai M; He C; Yin Z; Niu J; Wang Z; Qi X; Liu L; Yang Z; Guo W; Tie J; Bai W; Xia J; Cai H; Wang J; Wu K; Fan D; Han G
    Aliment Pharmacol Ther; 2014 Jul; 40(1):63-71. PubMed ID: 24832463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. L-Ornithine-l-aspartate in the management of hepatic encephalopathy: a meta-analysis.
    Jiang Q; Jiang XH; Zheng MH; Chen YP
    J Gastroenterol Hepatol; 2009 Jan; 24(1):9-14. PubMed ID: 18823442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study.
    Kircheis G; Nilius R; Held C; Berndt H; Buchner M; Görtelmeyer R; Hendricks R; Krüger B; Kuklinski B; Meister H; Otto HJ; Rink C; Rösch W; Stauch S
    Hepatology; 1997 Jun; 25(6):1351-60. PubMed ID: 9185752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of L-ornithine-L-aspartate as an adjuvant therapy in cirrhotic patients with hepatic encephalopathy.
    Abid S; Jafri W; Mumtaz K; Islam M; Abbas Z; Shah HA; Hamid S
    J Coll Physicians Surg Pak; 2011 Nov; 21(11):666-71. PubMed ID: 22078345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A double-blind, randomized, placebo-controlled trial of intravenous L-ornithine-L-aspartate on postural control in patients with cirrhosis.
    Schmid M; Peck-Radosavljevic M; König F; Mittermaier C; Gangl A; Ferenci P
    Liver Int; 2010 Apr; 30(4):574-82. PubMed ID: 20456040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. L-ornithine L-aspartate in bouts of overt hepatic encephalopathy.
    Sidhu SS; Sharma BC; Goyal O; Kishore H; Kaur N
    Hepatology; 2018 Feb; 67(2):700-710. PubMed ID: 28749571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of different drugs in the treatment of minimal hepatic encephalopathy: A network meta-analysis involving 826 patients based on 10 randomized controlled trials.
    Cai XJ; Wang L; Hu CM
    J Cell Biochem; 2018 Nov; 119(10):8336-8345. PubMed ID: 29932239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic and Pharmacodynamic Properties of L-Ornithine L-Aspartate (LOLA) in Hepatic Encephalopathy.
    Kircheis G; Lüth S
    Drugs; 2019 Feb; 79(Suppl 1):23-29. PubMed ID: 30706424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy.
    Mittal VV; Sharma BC; Sharma P; Sarin SK
    Eur J Gastroenterol Hepatol; 2011 Aug; 23(8):725-32. PubMed ID: 21646910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic review with network meta-analysis: the comparative effectiveness and safety of interventions in patients with overt hepatic encephalopathy.
    Zhu GQ; Shi KQ; Huang S; Wang LR; Lin YQ; Huang GQ; Chen YP; Braddock M; Zheng MH
    Aliment Pharmacol Ther; 2015 Apr; 41(7):624-35. PubMed ID: 25684317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of rifaximin, probiotics, and l-ornithine l-aspartate on minimal hepatic encephalopathy: a randomized controlled trial.
    Sharma K; Pant S; Misra S; Dwivedi M; Misra A; Narang S; Tewari R; Bhadoria AS
    Saudi J Gastroenterol; 2014; 20(4):225-32. PubMed ID: 25038208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A critical analysis of studies assessing L-ornithine-L-aspartate (LOLA) in hepatic encephalopathy treatment.
    Soárez PC; Oliveira AC; Padovan J; Parise ER; Ferraz MB
    Arq Gastroenterol; 2009; 46(3):241-7. PubMed ID: 19918694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.